The IPO flood keeps ris­ing with 4 more biotechs and a SPAC on their way to Nas­daq

Af­ter a record year for biotech IPOs in 2020, fore­casts were bull­ish on an­oth­er strong year show­ing for pub­lic of­fer­ings — and 2021 hasn’t dis­ap­point­ed so far. Now, a clutch of four biotechs chas­ing rare dis­ease and can­cer and a New York SPAC are ready to join the par­ty.

Three more com­pa­nies filed to head to Nas­daq on Tues­day, as well as a SPAC, with an ad­di­tion­al Dutch biotech fil­ing Fri­day. All in all, ear­ly days in­di­cate an­oth­er big year, at least to start, with 12 com­pa­nies ei­ther pric­ing or fil­ing their IPOs in the first 20 days of Jan­u­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA